Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Subjects With Normal Renal Function Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

NCT04209049
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

NCT03506854
View directory record Official record
Conditions
Renal Impairment
Interventions
ISIS 681257
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

NCT01289080
View directory record Official record
Conditions
Schizophrenia, Psychiatric Disorders
Interventions
OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

NCT05711381
View directory record Official record
Conditions
Renal Impairment
Interventions
HM15912
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tustin, California • Miami, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 7, 2026, 5:03 AM EDT
Completed No phase listed Observational

Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects

NCT00721994
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis
Interventions
Cormet Hip Resurfacing System
Device
Lead sponsor
Corin
Industry
Eligibility
Not listed
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
5
States / cities
Merritt Island, Florida • Sarasota, Florida • Springfield, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

NCT01309438
View directory record Official record
Conditions
Healthy, Renal Insufficiency
Interventions
Rivaroxaban (normal renal function), Rivaroxaban (mild and moderate renal impairment), Erythromycin (normal renal function), Erythromycin (mild and moderate renal function)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
35 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Orlando, Florida • Minneapolis, Minnesota • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

NCT00626249
View directory record Official record
Conditions
Mild Nephropathy, Moderate Nephropathy, Diabetes Mellitus
Interventions
Technosphere Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Minneapolis, Minnesota • Omaha, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

NCT06468826
View directory record Official record
Conditions
End-Stage Renal Disease (ESRD)
Interventions
Avacopan
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

NCT06496217
View directory record Official record
Conditions
Renal Impairment
Interventions
MBX 2109
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

NCT02442258
View directory record Official record
Conditions
Renal Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

NCT00824590
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2009 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

NCT02674581
View directory record Official record
Conditions
HIV Infections
Interventions
Oral BMS-663068 (pro-drug)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function

NCT02400307
View directory record Official record
Conditions
HIV
Interventions
Bictegravir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 79 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

NCT01240967
View directory record Official record
Conditions
Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2014 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

NCT02634437
View directory record Official record
Conditions
Renal Function
Interventions
Ulipristal acetate
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function

NCT01715259
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Abiraterone acetate: participants with end-stage renal disease, Abiraterone acetate: matched control participants with normal renal function
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2012 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

NCT03131479
View directory record Official record
Conditions
Renal Impairment
Interventions
LIK066
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

NCT01766154
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Tirofiban
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function

NCT00483860
View directory record Official record
Conditions
Solid Tumours
Interventions
Topotecan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Scottsdale, Arizona • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function

NCT06698549
View directory record Official record
Conditions
COVID 19
Interventions
ALG-097558
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Results available

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

NCT01393964
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608; HuLuc63)
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

NCT04476849
View directory record Official record
Conditions
Healthy Volunteers, Renal Impairment
Interventions
fezolinetant
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Garden Grove, California • Rialto, California • Clearwater, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency

NCT02020434
View directory record Official record
Conditions
Subjects With Varying Degrees of Renal Insufficiency and, Subjects With Normal Renal Function
Interventions
RPX7009 and RPX2014
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Sep 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

NCT02729038
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 7, 2026, 5:03 AM EDT